
    
      Materials and Methods:

      This is a randomized, double-blind, placebo-controlled study, patients will be randomly
      assigned to the TZD group and to the placebo group with a 6-month treatment period.

      Biomarkers will also examined before and 6 months post-treatment during the trial.

      The primary end-points will be the diagnosis of major cardiovascular events: myocardial
      infarction, overt heart failure, and surgery or coronary intervention for CAD.
    
  